Last Update: Aug 19, 2026 A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis ClinicalTrials.gov Identifier: [NCT06470048](https://clinicaltrials.gov/ct2/show/NCT06470048) Novartis Reference Number:CVAY736S12201 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous systemic sclerosis relative to placebo The study consists of the following periods: \* Screening Period, with a duration of up to 6 weeks; \* Treatment Period 1, with a duration of 52 weeks; \* Treatment Period 2 (Open-label treatment), with a duration of 52 weeks; \* Post-treatment Follow-up Period, with a duration of at least 20 weeks post last dose and up to 2 years. Condition Diffuse Cutaneous Systemic Sclerosis Phase Phase2 Overall Status Recruiting Number of Participants200 Start Date Oct 09, 2024 Completion Date Jul 31, 2034 Gender All Age(s) 18 Years - 70 Years (Adult, Older Adult) ## Interventions Drug ### Ianalumab subcutaneous (s.c.) injection as defined in the protocol Drug ### Placebo Ianalumab matching placebo subcutaneous (s.c.) injection as defined in the protocol ## Eligibility Criteria Key Inclusion Criteria: \* Male and female participants \\>= 18 and =\\< 70 years (at the time of the screening visit). \* Diagnosis of systemic sclerosis, as defined by the 2013 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) classification criteria for SSc (van den Hoogen et al 2013) and meet the dcSSc subset classification according to LeRoy (LeRoy 1988) \* Disease duration of =\\< 60 months (defined as time from the first non-Raynaud phenomenon manifestation, e.g., puffy hands, scleroderma, digital ulcers, arthralgia, dyspnea) \* mRSS units of \\>= 15 and =\\< 45 at the time of the screening visit \* Active disease that meets at least one of the following criteria at screening: \* Disease duration of =\\< 18 months defined as time from the first non-Raynaud phenomenon manifestation \* Increase in mRSS of \\>= 3 units compared with the most recent assessment performed within the previous 6 months \* Involvement of one new body area and an increase in mRSS of \\>= 2 units compared with the most recent assessment performed within the previous 6 months \* Involvement of two new body areas within the previous 6 months \* Elevated acute phase reactants (ESR) \\>= 30 mm/hr or high-sensitivity C-reactive protein (hsCRP) \\>= 6 mg/L) \* Presence of SSc-interstitial lung disease (ILD) and ATA autoantibody positivity \* Modified EUSTAR disease activity index (mDAI) ≥ 2.5 \* Participant must be positive for at least one of the following autoantibodies: \* anti-topoisomerase I (ATA) (also known as anti-SCL-70) \* anti-RNA polymerase III (anti-RNAP3) \* anti-nuclear antibody (ANA) (≥ 1:80) Participants who are positive only for ANA (while being negative for both ATA /anti-RNAP3) will be limited to 30% of the overall randomized study population. Key Exclusion Criteria: \* Rheumatic disease other than dcSSc, including limited cutaneous disease (lcSSc) or sine scleroderma at the screening visit. Secondary Sjogren's disease and scleroderma myopathy are not exclusionary. \* Positive anti-centromere antibody (ACA+) without positive ATA or anti-RNAP3 autoantibody result at the screening visit \* Previous improvement (decrease) in mRSS \\> 10 units \* Pulmonary disease with FVC ≤ 50% of predicted or diffusing capacity of the lung for carbon monoxide (DLCO, corrected for hemoglobin) ≤ 40% of predicted at the screening visit \* WHO Functional Class 3 or higher assessment for pulmonary arterial hypertension (PAH, as defined on right heart catheterization), receiving IV therapy for PAH or evidence of other moderately severe pulmonary disease \* Participants treated with cyclophosphamide within 12 weeks prior to Baseline. \* Prior use of a B-cell depleting therapy other than ianalumab (e.g., rituximab, other anti-CD20 mAb, anti-CD22 mAb, or anti-CD52 mAb) administered within 36 weeks prior to randomization, or as long as B cell count is less than the lower limit of normal or baseline value prior to receipt of B cell-depleting therapy (whichever is lower). \* Treatment with biologic agents, such as intravenous immunoglobulin or monoclonal antibodies, including marketed drugs, within 12 weeks or 5 half-lives (whichever is longer) prior to baseline visit, unless explicitly allowed in inclusion criteria. \* Treatment with any investigational agent within ≤ 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of the baseline visit. \* Use of anti-fibrotic agents including colchicine, D-penicillamine, pirfenidone, or tyrosine kinase inhibitors (e.g., nintedanib, nilotinib, imatinib, dasatinib) in the 4 weeks prior to baseline visit. Patients with SSc-ILD requiring antifibrotics for management of ILD during the study, as per investigator judgement, should be excluded. \* Previous treatment with chlorambucil, bone marrow transplantation or total lymphoid irradiation. \* Women of childbearing potential, defined as all women physiologically capable of becoming pregnant from menarche until becoming post-menopausal, unless they are using highly effective methods of contraception (failure rate \\< 1% per year) while taking study treatment and for 6 months after stopping study treatment. Other protocol-defined inclusion/exclusion criteria may apply. Argentina #### Novartis Investigative Site Recruiting CABA,Buenos Aires,C1221adc,Argentina #### Novartis Investigative Site Recruiting Caba,C1015abo,Argentina #### Novartis Investigative Site Recruiting Caba,C1427ccl,Argentina #### Novartis Investigative Site Recruiting CABA,Buenos Aires,C1280aeb,Argentina #### Novartis Investigative Site Recruiting San Miguel de Tucumán,T4000axl,Argentina Austria #### Novartis Investigative Site Recruiting Graz,8036,Austria Belgium #### Novartis Investigative Site Recruiting Leuven,3000,Belgium Brazil #### Novartis Investigative Site Recruiting Curitiba,Paraná,80030-110,Brazil #### Novartis Investigative Site Recruiting Porto Alegre,Rio Grande do Sul,90035-074,Brazil #### Novartis Investigative Site Recruiting São Paulo,São Paulo,04038-002,Brazil #### Novartis Investigative Site Recruiting São Paulo,São Paulo,05403-000,Brazil #### Novartis Investigative Site Recruiting Salvador,Estado de Bahia,40150-150,Brazil #### Novartis Investigative Site Recruiting Sao Jose Rio Preto,São Paulo,15090-000,Brazil China #### Novartis Investigative Site Recruiting Chengdu,Sichuan,610041,China #### Novartis Investigative Site Recruiting Beijing,100191,China #### Novartis Investigative Site Recruiting Nanning,Guangxi,530021,China #### Novartis Investigative Site Recruiting Beijing,100730,China #### Novartis Investigative Site Recruiting Tianjin,300052,China #### Novartis Investigative Site Recruiting Changchun,Jilin,130021,China #### Novartis Investigative Site Recruiting Zhengzhou,Henan,450003,China #### Novartis Investigative Site Recruiting Ningbo,Zhejiang,315016,China France #### Novartis Investigative Site Recruiting Le Mans,72000,France #### Novartis Investigative Site Recruiting Strasbourg,67000,France #### Novartis Investigative Site Recruiting Toulouse,31054,France #### Novartis Investigative Site Recruiting Montpellier,34295,France #### Novartis Investigative Site Recruiting Rennes,35033,France Germany #### Novartis Investigative Site Recruiting Berlin,13353,Germany #### Novartis Investigative Site Recruiting Würzburg,Bavaria,97080,Germany #### Novartis Investigative Site Recruiting Jena,Thuringia,07740,Germany Greece #### Novartis Investigative Site Recruiting Athens,115 21,Greece #### Novartis Investigative Site Recruiting Athens,115 27,Greece #### Novartis Investigative Site Recruiting Alexandroupoli,681 00,Greece Hungary #### Novartis Investigative Site Recruiting Pécs,Baranya,7623,Hungary #### Novartis Investigative Site Recruiting Debrecen,Hajdu Bihar Megye,4032,Hungary India #### Novartis Investigative Site Recruiting Mumbai,Maharashtra,400013,India Italy #### Novartis Investigative Site Recruiting Roma,RM,00168,Italy #### Novartis Investigative Site Recruiting Verona,VR,37134,Italy #### Novartis Investigative Site Recruiting Rozzano,MI,20089,Italy #### Novartis Investigative Site Recruiting Palermo,PA,90127,Italy #### Novartis Investigative Site Recruiting Pavia,PV,27100,Italy #### Novartis Investigative Site Recruiting Modena,MO,41124,Italy #### Novartis Investigative Site Recruiting Milan,MI,20100,Italy #### Novartis Investigative Site Recruiting Ancona,AN,60020,Italy Japan #### Novartis Investigative Site Recruiting Bunkyo-ku,Tokyo,113-8603,Japan #### Novartis Investigative Site Recruiting Kitakyushu,Fukuoka,8078556,Japan #### Novartis Investigative Site Recruiting Iruma-gun,Saitama,3500495,Japan #### Novartis Investigative Site Recruiting Fukuoka,8128582,Japan #### Novartis Investigative Site Recruiting Hiroshima,7348551,Japan #### Novartis Investigative Site Recruiting Nagoya,Aichi-ken,4578510,Japan #### Novartis Investigative Site Recruiting Sapporo,Hokkaido,0608543,Japan #### Novartis Investigative Site Recruiting Shinjuku Ku,Tokyo,1628666,Japan #### Novartis Investigative Site Recruiting Shinjuku-ku,Tokyo,1608582,Japan #### Novartis Investigative Site Recruiting Kyoto,6068507,Japan #### Novartis Investigative Site Recruiting Toyoake,Aichi-ken,4701192,Japan #### Novartis Investigative Site Recruiting Maebashi,Gunma,3718511,Japan #### Novartis Investigative Site Recruiting Sapporo,Hokkaido,060-8648,Japan #### Novartis Investigative Site Recruiting Chuo Ku,Tokyo,104-8560,Japan #### Novartis Investigative Site Recruiting Ishikawa,9208641,Japan #### Novartis Investigative Site Recruiting Toyama,Toyama,9300194,Japan #### Novartis Investigative Site Recruiting Suita,Osaka,5650871,Japan Malaysia #### Novartis Investigative Site Recruiting Kuala Lumpur,59100,Malaysia Mexico #### Novartis Investigative Site Recruiting Guadalajara,Jalisco,44650,Mexico #### Novartis Investigative Site Recruiting Mexico City,Mexico City,06700,Mexico Portugal #### Novartis Investigative Site Recruiting Lisbon,1649-035,Portugal #### Novartis Investigative Site Recruiting Coimbra,3004-561,Portugal #### Novartis Investigative Site Recruiting Vila Nova de Gaia,4434-502,Portugal South Korea #### Novartis Investigative Site Recruiting Busan,49241,South Korea #### Novartis Investigative Site Recruiting Seoul,04763,South Korea #### Novartis Investigative Site Recruiting Seoul,06273,South Korea Spain #### Novartis Investigative Site Recruiting Barcelona,08041,Spain #### Novartis Investigative Site Recruiting Madrid,28009,Spain #### Novartis Investigative Site Recruiting Valencia,Valencia,46017,Spain #### Novartis Investigative Site Recruiting Salamanca,37007,Spain #### Novartis Investigative Site Recruiting Málaga,Andalusia,29009,Spain Taiwan #### Novartis Investigative Site Recruiting Taichung,40447,Taiwan #### Novartis Investigative Site Recruiting Changhua,50006,Taiwan #### Novartis Investigative Site Recruiting Taoyuan,33305,Taiwan #### Novartis Investigative Site Recruiting Kaohsiung City,833,Taiwan Thailand #### Novartis Investigative Site Recruiting Khon Kaen,THA,40002,Thailand #### Novartis Investigative Site Recruiting Bangkok,10400,Thailand Turkey (Türkiye) #### Novartis Investigative Site Recruiting Istanbul,Fatih,34093,Turkey (Türkiye) #### Novartis Investigative Site Recruiting Ankara,Sihhiye-Altindag,06230,Turkey (Türkiye) #### Novartis Investigative Site Recruiting Ankara,Yenimahalle,06500,Turkey (Türkiye) United States #### Clinical Res Of W Florida Recruiting Clearwater,Florida,33765,United States ###### Amber Tipker Phone: [+1 727 466 0078]() Email: ###### Rodney Daniel #### West Tennessee Research Institute Recruiting Jackson,Tennessee,38305,United States ###### Jacob A Aelion ###### Sherry Wiggins Phone: [17316330119](tel:17316330119) Email: #### Prolato Clinical Research Center Recruiting Houston,Texas,77054,United States ###### Michelle Eisenberg ###### Mohammad Alsayed Phone: [+1 832 338 9118]() Email: #### Uni Of Michigan Health System Recruiting Ann Arbor,Michigan,48109,United States ###### Carleigh Zahn ###### Christopher Floyd Phone: [+1 734 936 5504]() Email: #### Arizona Arthritis and Rheumatology Research PLLC Recruiting Mesa,Arizona,85202,United States ###### Debra Mc Dermed Phone: [+1 602 386 4970]() Email: ###### Nehad Soloman #### GNP Research Recruiting Cooper City,Florida,33024,United States ###### Mark Jaffe ###### Melissa Pierce Phone: [+1 754 248 3589]() Email: #### Clinical Research Inst of MI Recruiting Saint Clair Shores,Michigan,48081,United States ###### Amelia Laurence Phone: [+1 586 777 7577]() Email: ###### Andrew Sulich #### Novel Research LLC Recruiting Bellaire,Texas,77401,United States ###### Hassan Khan Email: ###### Wajeeha Yousaf #### Hoag Hospital Recruiting Newport Beach,California,92663,United States ###### Christine Thai ###### Vicki Tan Phone: [+1 949 791 3049]() Email: #### UMC New Orleans Recruiting New Orleans,Louisiana,70112,United States ###### Sean Barry Email: ###### Stephen Lindsey #### IRIS Research and Development Recruiting Plantation,Florida,33324,United States ###### Guillermo Valenzuela ###### Jhon Galindo Phone: [+1 954 476 2338]() Email: #### University of Chicago Hospitals Recruiting Chicago,Illinois,60637,United States ###### J Heannhehbelle Rosier Phone: [+1 773 702 3853]() Email: ###### Michael Macklin #### UCLA Recruiting Los Angeles,California,90095,United States ###### Lauren Nam Phone: [+1 310 488 0162]() Email: ###### Suzanne Kafaja #### Wayne State University Recruiting Detroit,Michigan,48201,United States ###### Biljana Basic-Panic Email: ###### Ilyes Benchaala #### Hospital for Special Surgery Recruiting New York,New York,10021,United States ###### Kimberly Showalter Lakin ###### Liza Morales Phone: [+1 212 774 2596]() Email: #### Arthritis and Rheumatology Ins Recruiting Allen,Texas,75035,United States ###### Megha Patel Banker ###### Samina Shehzad Email: ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: #### Novartis Pharmaceuticals Phone: [ 1-888-669-6682](tel:1-888-669-6682) Email: